The Function and Mechanisms of Nurr1 Action in Midbrain Dopaminergic Neurons, from Development and Maintenance to Survival

International Review of Neurobiology

Volumn 102, Issue , 2012, Pages 1-22

  Luo, Yu ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GUANOSINE TRIPHOSPHATASE; MESSENGER RNA; NUCLEAR RECEPTOR RELATED FACTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULTHOOD; ARTICLE; DEVELOPMENT; DOPAMINERGIC NERVE CELL; GENE; GENE PRODUCT; HUMAN; IN VIVO STUDY; LIFE CYCLE; MESENCEPHALON; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SURVIVAL; VASOACTIVE INTESTINAL POLYPEPTIDE GENE;

EID: 84862851101     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386986-9.00001-6     Document Type: Chapter

References (98)

1. Aarnisalo P., Kim C.H., Lee J.W., Perlmann T. Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1. J. Biol. Chem. 2002, 277:35118-35123.
2. Adler E.M., Fink J.S. Calcium regulation of vasoactive intestinal polypeptide mRNA abundance in SH-SY5Y human neuroblastoma cells. J. Neurochem. 1993, 61:727-737.
3. Agoston D.V., Bravo D.T., Waschek J.A. Expression of a chimeric VIP gene is targeted to the intestine in transgenic mice. J. Neurosci. Res. 1990, 27:479-486.
4. Backman C., Perlmann T., Wallen A., Hoffer B.J., Morales M. A selective group of dopaminergic neurons express Nurr1 in the adult mouse brain. Brain Res. 1999, 851:125-132.
5. Barbeau A. Parkinson's disease: clinical features and etiopahthology. Handbook of Clinical Neurology 1986, 87-108. Elsevier Science Publishers, B.V., Amsterdam. P.J. Viken, G.W. Bruyn, H.L. Klawans (Eds.).
6. Bialecka M., Hui S., Klodowska-Duda G., Opala G., Tan E.K., Drozdzik M. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease. Neurosci. Lett. 2005, 390:1-3.
7. Bonifati V., Rizzu P., Squitieri F., Krieger E., Vanacore N., van Swieten J.C., Brice A., van Duijn C.M., Oostra B., Meco G., Heutink P. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 2003, 24:159-160.
8. Bowers W.J., Howard D.F., Federoff H.J. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease. Exp. Neurol. 1997, 144:58-68.
9. Burbach J.P., Smits S., Smidt M.P. Transcription factors in the development of midbrain dopamine neurons. Ann. N. Y. Acad. Sci. 2003, 991:61-68.
10. Caiazzo M., Dell'Anno M.T., Dvoretskova E., Lazarevic D., Taverna S., Leo D., Sotnikova T.D., Menegon A., Roncaglia P., Colciago G., Russo G., Carninci P., et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011, 476:224-227.
11. Carlsson A., Lindqvist M., Magnusson T., Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 1958, 127:471.
12. Castillo S.O., Xiao Q., Kostrouch Z., Dozin B., Nikodem V.M. A divergent role of COOH-terminal domains in Nurr1 and Nur77 transactivation. Gene Expr. 1998, 7:1-12.
13. Castillo S.O., Baffi J.S., Palkovits M., Goldstein D.S., Kopin I.J., Witta J., Magnuson M.A., Nikodem V.M. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol. Cell. Neurosci. 1998, 11:36-46.
14. Castro D.S., Arvidsson M., Bondesson Bolin M., Perlmann T. Activity of the Nurr1 carboxyl-terminal domain depends on cell type and integrity of the activation function 2. J. Biol. Chem. 1999, 274:37483-37490.
15. Dahlstrom A., Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system I. Demonstration of monoamines in the cell nodies of brain stem neurons. Acta Physiol. Scand. Suppl. 1964, Suppl. 232:1-55.
16. Dahlstrom A., Fuxe K. Localization of monoamines in the lower brain stem. Experientia 1964, 20:398-399.
17. Delgado M., Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 2003, 17:944-946.
18. Dreyer S.D., Zhou G., Baldini A., Winterpacht A., Zabel B., Cole W., Johnson R.L., Lee B. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat. Genet. 1998, 19:47-50.
19. Duvoisin R.C. Overview of Parkinson's disease. Ann. N. Y. Acad. Sci. 1992, 648:187-193.
20. Eells J.B., Rives J.E., Yeung S.K., Nikodem V.M. In vitro regulated expression of tyrosine hydroxylase in ventral midbrain neurons from Nurr1-null mouse pups. J. Neurosci. Res. 2001, 64:322-330.
21. Eells J.B., Lipska B.K., Yeung S.K., Misler J.A., Nikodem V.M. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav. Brain Res. 2002, 136:267-275.
22. Eskay R.L., Eiden L.E. Interleukin-1 alpha and tumor necrosis factor-alpha differentially regulate enkephalin, vasoactive intestinal polypeptide, neurotensin, and substance P biosynthesis in chromaffin cells. Endocrinology 1992, 130:2252-2258.
23. Fink J.S., Verhave M., Walton K., Mandel G., Goodman R.H. Cyclic AMP- and phorbol ester-induced transcriptional activation are mediated by the same enhancer element in the human vasoactive intestinal peptide gene. J. Biol. Chem. 1991, 266:3882-3887.
24. Galleguillos D., Vecchiola A., Fuentealba J.A., Ojeda V., Alvarez K., Gomez A., Andres M.E. PIASgamma represses the transcriptional activation induced by the nuclear receptor Nurr1. J. Biol. Chem. 2004, 279:2005-2011.
25. Giguere V. Orphan nuclear receptors: from gene to function. Endocr. Rev. 1999, 20:689-725.
26. Girard B.M., May V., Bora S.H., Fina F., Braas K.M. Regulation of neurotrophic peptide expression in sympathetic neurons: quantitative analysis using radioimmunoassay and real-time quantitative polymerase chain reaction. Regul. Pept. 2002, 109:89-101.
27. Grimes D.A., Han F., Panisset M., Racacho L., Xiao F., Zou R., Westaff K., Bulman D.E. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov. Disord. 2006, 21:906-909.
28. Hahm S.H., Eiden L.E. Tissue-specific expression of the vasoactive intestinal peptide gene requires both an upstream tissue specifier element and the 5' proximal cyclic AMP-responsive element. J. Neurochem. 1996, 67:1872-1881.
29. Hahm S.H., Eiden L.E. Five discrete cis-active domains direct cell type-specific transcription of the vasoactive intestinal peptide (VIP) gene. J. Biol. Chem. 1998, 273:17086-17094.
30. Hahm S.H., Eiden L.E. Cis-regulatory elements controlling basal and inducible VIP gene transcription. Ann. N. Y. Acad. Sci. 1998, 865:10-26.
31. Hermanson E., Borgius L., Bergsland M., Joodmardi E., Perlmann T. Neuropilin1 is a direct downstream target of Nurr1 in the developing brain stem. J. Neurochem. 2006, 97:1403-1411.
32. Hynes M., Rosenthal A. Specification of dopaminergic and serotonergic neurons in the vertebrate CNS. Curr. Opin. Neurobiol. 1999, 9:26-36.
33. Iwatsubo T., Ito G., Takatori S., Hannno Y., Kuwahara T. Pathogenesis of Parkinson's disease: implications from familial Parkinson's disease. Rinsho Shinkeigaku 2005, 45:899-901.
34. Jacobs F.M., van Erp S., van der Linden A.J., von Oerthel L., Burbach J.P., Smidt M.P. Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. Development 2009, 136:531-540.
35. Jacobs F.M., van der Linden A.J., Wang Y., von Oerthel L., Sul H.S., Burbach J.P., Smidt M.P. Identification of Dlk1, Ptpru and Klhl1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons. Development 2009, 136:2363-2373.
36. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv. Neurol. 1987, 45:1-18.
37. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 1998, 44:S72-S84.
38. Jiang C., Wan X., He Y., Pan T., Jankovic J., Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol. 2005, 191:154-162.
39. Joseph B., Wallen-Mackenzie A., Benoit G., Murata T., Joodmardi E., Okret S., Perlmann T. p57(Kip2) cooperates with Nurr1 in developing dopamine cells. Proc. Natl. Acad. Sci. USA 2003, 100:15619-15624.
40. Kadkhodaei B., Ito T., Joodmardi E., Mattsson B., Rouillard C., Carta M., Muramatsu S., Sumi-Ichinose C., Nomura T., Metzger D., Chambon P., Lindqvist E., et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 2009, 29:15923-15932.
41. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
42. Kopin I.J. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Adv. Neurol. 1987, 45:137-144.
43. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
44. Law S.W., Conneely O.M., DeMayo F.J., O'Malley B.W. Identification of a new brain-specific transcription factor, NURR1. Mol. Endocrinol. 1992, 6:2129-2135.
45. Le W., Conneely O.M., He Y., Jankovic J., Appel S.H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 1999, 73:2218-2221.
46. Le W.D., Xu P., Jankovic J., Jiang H., Appel S.H., Smith R.G., Vassilatis D.K. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 2003, 33:85-89.
47. Le W., Pan T., Huang M., Xu P., Xie W., Zhu W., Zhang X., Deng H., Jankovic J. Decreased NURR1 gene expression in patients with Parkinson's disease. J. Neurol. Sci. 2008, 273:29-33.
48. Lee H.S., Bae E.J., Yi S.H., Shim J.W., Jo A.Y., Kang J.S., Yoon E.H., Rhee Y.H., Park C.H., Koh H.C., Kim H.J., Choi H.S., et al. Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival. Stem Cells 2010, 28:501-512.
49. Lincoln S., Vaughan J., Wood N., Baker M., Adamson J., Gwinn-Hardy K., Lynch T., Hardy J., Farrer M. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 1999, 10:427-429.
50. Luo Y., Henricksen L.A., Giuliano R.E., Prifti L., Callahan L.M., Federoff H.J. VIP is a transcriptional target of Nurr1 in dopaminergic cells. Exp. Neurol. 2007, 203:221-232.
51. Luo Y., Xing F., Guiliano R., Federoff H.J. Identification of a novel Nurr1-interacting protein. J. Neurosci. 2008, 28:9277-9286.
52. Luo Y., Sarabi S.A., Backman C., Shan L., Hoffer B., Federoff H. Expression pattern of NuIP gene in adult mouse brain. Brain Res. 2009, 1302:42-53.
53. Luo Y., Wang Y., Kuang S.Y., Chiang Y.H., Hoffer B. Decreased level of Nurr1 in heterozygous young adult mice leads to exacerbated acute and long-term toxicity after repeated methamphetamine exposure. PLoS One 2010, 5:e15193.
54. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
55. Moody T.W., Hill J.M., Jensen R.T. VIP as a trophic factor in the CNS and cancer cells. Peptides 2003, 24:163-177.
56. Nunes I., Tovmasian L.T., Silva R.M., Burke R.E., Goff S.P. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. USA 2003, 100:4245-4250.
57. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D.E., Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 2000, 854:257-262.
58. Perlmann T., Jansson L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev. 1995, 9:769-782.
59. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., Sanges G., Stenroos E.S., Pho L.T., Schaffer A.A., Lazzarini A.M., Nussbaum R.L., et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996, 274:1197-1199.
60. Rao M.S., Symes A., Malik N., Shoyab M., Fink J.S., Landis S.C. Oncostatin M regulates VIP expression in a human neuroblastoma cell line. Neuroreport 1992, 3:865-868.
61. Rojas P., Joodmardi E., Hong Y., Perlmann T., Ogren S.O. Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol. Psychiatry 2007, 12:756-766.
62. Rosenthal A. Specification and survival of dopaminergic neurons in the mammalian midbrain. Adv. Pharmacol. 1998, 42:908-911.
63. Rostene W.H. Neurobiological and neuroendocrine functions of the vasoactive intestinal peptide (VIP). Prog. Neurobiol. 1984, 22:103-129.
64. Sacchetti P., Mitchell T.R., Granneman J.G., Bannon M.J. Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J. Neurochem. 2001, 76:1565-1572.
65. Sakurada K., Ohshima-Sakurada M., Palmer T.D., Gage F.H. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 1999, 126:4017-4026.
66. Saucedo-Cardenas O., Quintana-Hau J.D., Le W.D., Smidt M.P., Cox J.J., De Mayo F., Burbach J.P., Conneely O.M. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. USA 1998, 95:4013-4018.
67. Simon H.H., Saueressig H., Wurst W., Goulding M.D., O'Leary D.D. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci. 2001, 21:3126-3134.
68. Smidt M.P., van Schaick H.S., Lanctot C., Tremblay J.J., Cox J.J., van der Kleij A.A., Wolterink G., Drouin J., Burbach J.P. A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc. Natl. Acad. Sci. USA 1997, 94:13305-13310.
69. Smidt M.P., Asbreuk C.H., Cox J.J., Chen H., Johnson R.L., Burbach J.P. A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat. Neurosci. 2000, 3:337-341.
70. Smidt M.P., Smits S.M., Burbach J.P. Molecular mechanisms underlying midbrain dopamine neuron development and function. Eur. J. Pharmacol. 2003, 480:75-88.
71. Smith R.G. The aging process: where are the drug opportunities?. Curr. Opin. Chem. Biol. 2000, 4:371-376.
72. Symes A.J., Rao M.S., Lewis S.E., Landis S.C., Hyman S.E., Fink J.S. Ciliary neurotrophic factor coordinately activates transcription of neuropeptide genes in a neuroblastoma cell line. Proc. Natl. Acad. Sci. USA 1993, 90:572-576.
73. Symes A., Lewis S., Corpus L., Rajan P., Hyman S.E., Fink J.S. STAT proteins participate in the regulation of the vasoactive intestinal peptide gene by the ciliary neurotrophic factor family of cytokines. Mol. Endocrinol. 1994, 8:1750-1763.
74. Symes A.J., Corpus L., Fink J.S. Differences in nuclear signaling by leukemia inhibitory factor and interferon-gamma: the role of STAT proteins in regulating vasoactive intestinal peptide gene expression. J. Neurochem. 1995, 65:1926-1933.
75. Tornqvist N., Hermanson E., Perlmann T., Stromberg I. Generation of tyrosine hydroxylase-immunoreactive neurons in ventral mesencephalic tissue of Nurr1 deficient mice. Brain Res. Dev. Brain Res. 2002, 133:37-47.
76. Tsukada T., Fink J.S., Mandel G., Goodman R.H. Identification of a region in the human vasoactive intestinal polypeptide gene responsible for regulation by cyclic AMP. J. Biol. Chem. 1987, 262:8743-8747.
77. van den Munckhof P., Luk K.C., Ste-Marie L., Montgomery J., Blanchet P.J., Sadikot A.F., Drouin J. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 2003, 130:2535-2542.
78. Volpicelli F., Caiazzo M., Greco D., Consales C., Leone L., Perrone-Capano C., Colucci D'Amato L., di Porzio U. Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. J. Neurochem. 2007, 102:441-453.
79. Vuillermot S., Feldon J., Meyer U. Relationship between sensorimotor gating deficits and dopaminergic neuroanatomy in Nurr1-deficient mice. Exp. Neurol. 2011, 232:22-32.
80. Vuillermot S., Joodmardi E., Perlmann T., Ove Ogren S., Feldon J., Meyer U. Schizophrenia-relevant behaviors in a genetic mouse model of constitutive Nurr1 deficiency. Genes Brain Behav. 2011, 10:589-603.
81. Wagner J., Akerud P., Castro D.S., Holm P.C., Canals J.M., Snyder E.Y., Perlmann T., Arenas E. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat. Biotechnol. 1999, 17:653-659.
82. Wallen A., Perlmann T. Transcriptional control of dopamine neuron development. Ann. N. Y. Acad. Sci. 2003, 991:48-60.
83. Wallen A., Zetterstrom R.H., Solomin L., Arvidsson M., Olson L., Perlmann T. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. Exp. Cell Res. 1999, 253:737-746.
84. Wallen A.A., Castro D.S., Zetterstrom R.H., Karlen M., Olson L., Ericson J., Perlmann T. Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem. Mol. Cell. Neurosci. 2001, 18:649-663.
85. Wang Z., Benoit G., Liu J., Prasad S., Aarnisalo P., Liu X., Xu H., Walker N.P., Perlmann T. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 2003, 423:555-560.
86. Wansa K.D., Harris J.M., Muscat G.E. The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment. J. Biol. Chem. 2002, 277:33001-33011.
87. Waschek J.A., Pruss R.M., Siegel R.E., Eiden L.E., Bader M.F., Aunis D. Regulation of enkephalin, VIP, and chromogranin biosynthesis in actively secreting chromaffin cells. Ann. N. Y. Acad. Sci. 1987, 493:308-323.
88. Waschek J.A., Hsu C.M., Eiden L.E. Lineage-specific regulation of the vasoactive intestinal peptide gene in neuroblastoma cells is conferred by 5.2 kilobases of 5'-flanking sequence. Proc. Natl. Acad. Sci. USA 1988, 85:9547-9551.
89. Wilson T.E., Fahrner T.J., Johnston M., Milbrandt J. Identification of the DNA binding site for NGFI-B by genetic selection in yeast. Science 1991, 252:1296-1300.
90. Wilson T.E., Paulsen R.E., Padgett K.A., Milbrandt J. Participation of non-zinc finger residues in DNA binding by two nuclear orphan receptors. Science 1992, 256:107-110.
91. Witta J., Baffi J.S., Palkovits M., Mezey E., Castillo S.O., Nikodem V.M. Nigrostriatal innervation is preserved in Nurr1-null mice, although dopaminergic neuron precursors are arrested from terminal differentiation. Brain Res. Mol. Brain Res. 2000, 84:67-78.
92. Xiao Q., Castillo S.O., Nikodem V.M. Distribution of messenger RNAs for the orphan nuclear receptors Nurr1 and Nur77 (NGFI-B) in adult rat brain using in situ hybridization. Neuroscience 1996, 75:221-230.
93. Xu P.Y., Liang R., Jankovic J., Hunter C., Zeng Y.X., Ashizawa T., Lai D., Le W.D. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology 2002, 58:881-884.
94. Zetterstrom R.H., Williams R., Perlmann T., Olson L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res. Mol. Brain Res. 1996, 41:111-120.
95. Zetterstrom R.H., Solomin L., Mitsiadis T., Olson L., Perlmann T. Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol. Endocrinol. 1996, 10:1656-1666.
96. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997, 276:248-250.
97. Zhang L., Le W., Xie W., Dani J.A. Age-related changes in dopamine signaling in Nurr1deficient mice as a model of Parkinson's disease. Neurobiol. Aging. 2012, 33(5):1001.e7-1001.e16.
98. Zheng K., Heydari B., Simon D.K. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch. Neurol. 2003, 60:722-725.